AntipROTOzoal Activity of Achillea ptarmica (Asteraceae) and Its Main Alkamide Constituents †

Julia B. Althaus 1, Marcel Kaiser 2,3, Reto Brun 2,3 and Thomas J. Schmidt 1,*

1 Institut für Pharmazeutische Biologie und Phytochemie (IPBP), University of Münster, PharmaCampus, Corrensstraße 48, Münster D-48149, Germany; E-Mail: julia.althaus@uni-muenster.de
2 Swiss Tropical and Public Health Institute (Swiss TPH), Socinstraße 57, Basel CH-4002, Switzerland; E-Mails: Marcel.Kaiser@unibas.ch (M.K.); Reto.Brun@unibas.ch (R.B.)
3 University of Basel, Petersplatz 1, Basel CH-4003, Switzerland

† Part of Thesis. A preliminary account on this work has been published in abstract form (Planta Med. 2013, 79, 1129).

* Author to whom correspondence should be addressed; E-Mail: thomschm@uni-muenster.de; Tel.: +49-251-83-33378; Fax: +49-251-83-38341.

Received: 17 March 2014; in revised form: 14 May 2014 / Accepted: 15 May 2014 / Published: 20 May 2014

Abstract: In the course of our ongoing screening of plants of the family Asteraceae for antiprotozoal activity, a CH2Cl2-extract from the flowering aerial parts of Achillea ptarmica L. (sneezewort yarrow) was found to be active in vitro against Trypanosoma brucei rhodesiense (IC50 = 0.67 µg/mL) and Plasmodium falciparum (IC50 = 6.6 µg/mL). Bioassay guided fractionation led to the isolation and identification of five alkamides from the most active fractions. Pellitorine and 8,9-Z-dehyropellitorine are the main components of the extract. Beside these olefinic acid amides, four alkamides with diene-diynyl structures were isolated. All alkamides were tested for antiprotozoal activity in vitro. Pellitorine was the most active compound so far within this study against P. falciparum (IC50 = 3.3 µg/mL), while 8,9-Z-dehydropellitorine was most active against T. b. rhodesiense (IC50 = 2.0 µg/mL). The activity of pure pellitorine against Plasmodium is higher than that of the crude extract and thus explains the activity of the latter. None of the isolated alkamides, however, was as active against T. b. rhodesiense as the crude extract whose antitrypanosomal activity must therefore be due to a synergistic effect of the isolated compounds or to more active yet to be identified constituents.
**Keywords:** Achillea ptarmica; antiprotozoal activity; alkamide; Plasmodium falciparum; Trypanosoma brucei rhodesiense; Trypanosoma cruzi; Leishmania donovani

1. Introduction

Plants of the Asteraceae (sunflower) family are one of the main focuses in our search for natural products with activity against the major protozoan pathogens responsible for human diseases, *i.e.*, *Plasmodium*, *Trypanosoma* and *Leishmania* species [1–7]. In this screening, plants from this family have repeatedly yielded natural compounds with interesting activity against these parasites, especially *T. brucei rhodesiense* (*Tbr*), the causative agent of the East African form of human trypanosomiasis (sleeping sickness). Most of these compounds belong to the characteristic class of sesquiterpene lactones [4,5], but we have also reported on antiprotozoal activity of some flavonoids and a chromene derivative from the Asteraceae [6,7]. Generally, IC$_{50}$ values < 1 µg/mL against *Tbr* are considered a promising activity level for crude extracts. In the present study, a dichloromethane extract of flowering aerial parts of *Achillea ptarmica* L. (sneezewort yarrow) was found to display interesting anti-*Tbr* activity with an IC$_{50}$ of 0.67 µg/mL and relatively moderate cytotoxicity. Furthermore, it also displayed moderate antiplasmodial activity against the etiologic agent of tropical malaria, *P. falciparum* (*Pf*, IC$_{50}$ 6.6 µg/mL).

*A. ptarmica*, unlike its relative *A. millefolium*, has not been reported to contain sesquiterpene lactones. Its main constituents, besides some essential oil [8] and flavonoids [9], are known to be alkylamides (“alkamides”), *i.e.*, carboxamides of olefinic and polyynic carboxylic acids with various amine components [10,11]. Such carboxamides have previously been reported to possess local anaesthetic and insecticidal [10,12] as well as anti-inflammatory and immunomodulating [13] activities. The major aim of this work was therefore to identify the chemical constituents responsible for the antiprotozoal activity.

2. Results and Discussion

2.1. Antiprotozoal Activity of Achillea Crude Extracts

During our screening of Asteraceae extracts, we investigated, among others, a dichloromethane extract of flowering aerial parts of *Achillea ptarmica* which displayed an interesting level of activity against *Tbr* and moderate activity against *Pf*, while being essentially inactive against *T. cruzi* (*Tcr*; Chagas disease) and *Leishmania donovani* (*Ldo*; visceral leishmaniasis). The biological data are reported in Table 1. It is especially noteworthy that the cytotoxic activity against rat skeletal myoblasts (L6 cell line) used as control cells was over 40 times lower, so that this extract also displayed a favorable selectivity against *Tbr*. Interestingly, an extract of *A. millefolium* (same plant parts, but obtained with diethyl ether) displayed a dissimilar activity pattern with somewhat higher activity against *Pf*, but negligibly low activity against the trypanosomatid parasites. The extract of *A. ptarmica* was therefore chosen for a detailed study of its potential antitransplasmodial as well as antiplasmodial constituents.
Table 1. *In vitro* antiprotozoal and cytotoxic activity [IC_{50} values in µg/mL; values in µM of pure compounds are reported in brackets] of crude Asteraceae extracts and of the alkamides isolated from *A. ptarmica*. Selectivity indices (SI) represent the ratio of cytotoxic over antiprotozoal IC_{50} values. Data are means of two independent determinations ± deviation from mean value.

|            | Tbr  | Tcr  | Ldo  | Pf   | Tox. L6 | SI   | SI   |
|------------|------|------|------|------|---------|------|------|
| **Crude extracts** |      |      |      |      |         |      |      |
| *A. ptarmica* (aerial flowering parts; CH$_2$Cl$_2$-extract) | 0.67 ± 0.35 | 43.7 ± 8.1 | 14.9 ± 0.7 | 6.58 a ± 1.15 | 27.9 ± 8.0 | 41.64 | 4.24 |
| *A. millefolium* (aerial flowering parts; Et$_2$O-extract) | 23.5 ± 1.5 | 44.7 ± 4.5 | 6.76 ± 2.51 | 2.82 a ± 0.26 | 41.2 ± 13.0 | 1.75 | 14.6 |
| *E. purpurea* (flowering aerial parts; CH$_2$Cl$_2$-extract) | 3.70 ± 1.71 | >10 | >10 c | 4.39 ± 0.31 b | 52.5 ± 2.1 | 14.2 | 12.0 |
| *A. pyrethrum* (roots, CH$_2$Cl$_2$-extract) | >10 c | 8.83 ± 0.75 | 4.22 ± 1.57 | 3.04 b ± 0.07 | 13.4 ± 3.2 | <1.34 | 4.41 |
| **Isolated alkamides** |      |      |      |      |         |      |      |
| Pellitorine (#1) | 5.35 ± 0.54 (24.0) | 8.45 ± 1.08 (37.9) | 5.96 ± 0.16 (26.7) | 3.26 b ± 0.53 (14.6) | 45.5 ± 9.1 (201.8) | 8.41 | 13.85 |
| 8,9-Z-Dehydropellitorine (#2) | 2.00 ± 0.06 (9.1) | 14.2 ± 2.5 (64.3) | 5.01 ± 0.12 (22.7) | 6.48 b ± 0.55 (29.3) | 16.5 ± 0.2 (74.7) | 8.25 | 2.55 |
| (#3) | 6.66 ± 0.22 (29.1) | 19.9 ± 1.5 (86.9) | 8.87 ± 1.33 (38.7) | 5.84 b ± 0.17 (25.5) | 46.1 ± 3.2 (201.3) | 6.92 | 7.89 |
| (4+5) (3:1 mixture) | 3.50 ± 0.44 (9.1) | 8.36 ± 2.90 (64.3) | 11.8 ± 0.1 (38.7) | 6.89 ± 0.21 b (25.5) | 43.4 ± 5.0 (201.3) | 12.4 | 6.30 |
| Anacycline (#6) | 5.12 ± 0.95 (18.9) | 42.0 ± 4.5 (154.9) | >100 | 7.23 ± 0.40 b (26.7) | 48.7 ± 1.1 (18.0) | 9.5 | 6.74 |
| **Positive controls** |      |      |      |      |         |      |      |
| Melarsoprol | 0.003 ± 0.001 (0.008) |      |      |      |         |      |      |
| Benznidazole | 0.439 ± 0.094 (1.688) |      |      |      |         |      |      |
| Miltefosine | 0.127 ± 0.052 (0.312) |      |      |      |         |      |      |
| Chloroquine | 0.080 a ± 0.003 (0.250) |      |      |      |         |      |      |
| Chloroquine | 0.003 b ± 0.001 (0.009) |      |      |      |         |      |      |
| Podophyllotoxin | 0.008 ± 0.001 (0.019) |      |      |      |         |      |      |

* K1 strain; b NF54 strain; c preliminary data from 2-concentration assay conducted at 2 and 10 µg/mL.
2.2. Bioassay-Guided Fractionation of Achillea ptarmica Extract and Isolation of Alkamides

Using a gradient of hexane/ethyl acetate the dichloromethane extract was separated by column chromatography (CC) into 30 fractions which were combined after TLC control (see Experimental Section). All fractions were analyzed by UHPLC/+ESI QTOF MSMS and representative samples chosen for re-evaluation of their antiprotozoal activity. At this stage, each of the chosen fractions was tested for percent growth inhibitory activity at two concentrations (see Table 2).

Table 2. In vitro growth inhibition [%] at two concentrations of the A. ptarmica crude extract and selected subfractions against the various parasites.

|       | Tbr 10 µg/mL | Tbr 2 µg/mL | Tcr 10 µg/mL | Tcr 2 µg/mL | Ldo 10 µg/mL | Ldo 2 µg/mL | Pf (NF54) 10 µg/mL | Pf (NF54) 2 µg/mL |
|-------|-------------|-------------|-------------|-------------|-------------|-------------|--------------------|--------------------|
| Total extract | 100 | 0 | 1 | 3.4 | 19.4 | 9.4 | 63.8 | 6.1 |
| II | 4.3 | 25 | 0.6 | 0 | 8.9 | 5.1 | 5 | 4.7 |
| IV | 7.2 | 0 | 0 | 16.6 | 27.5 | 15.3 | 6 | 0 |
| Vb | 0 | 25 | 0 | 0 | 17.8 | 11.8 | 0 | 3.9 |
| XVI | 45.3 | 0 | 21.1 | 21.9 | 25.4 | 9.2 | 47.1 | 2.5 |
| XX | 66.8 | 0 | 18.9 | 0 | 17.2 | 21.7 | 9.8 | 0 |
| XXII | 90.2 | 6.4 | 8.5 | 0 | 35.7 | 8 | 35.7 | 7.7 |
| XXIII | 99.9 | 0 | 4.2 | 0 | 32.4 | 9.1 | 96.8 | 3.9 |
| XXV | 100 | 0 | 3.9 | 0 | 53.6 | 10.1 | 99.9 | 13.7 |
| XXVIII | 100 | 9.4 | 0 | 0 | 42.1 | 10 | 99.6 | 11.7 |

Obviously, the antitrypanosomal as well as antiplasmodial activity was concentrated in the later fractions. Subsequently, the major constituents were isolated from these fractions or directly neighboring fractions containing the same constituents. Thus, from fractions XXI, XXII, XXIII, XXV and XXVIII, the main alkamides 1–6 were isolated (Figure 1). Compounds 4 and 5 could only be obtained as a mixture containing them in a ratio of approximately 3:1. All compounds were unambiguously identified on the grounds of their exact masses as obtained from UHPLC/+ESI QTOF MSMS analyses (see Figure 2) as well as their ¹H-NMR data, which were in full agreement with literature values [10,11,14].

Figure 1. Structures of isolated compounds.
Figure 2. UHPLC/+ESI QTOF MSMS analysis of isolated compounds. Magenta: UV chromatogram at 260 nm; blue: Base peak chromatogram m/z 100–500. (A) CH₂Cl₂ extract of A. ptarmica (1 mg/mL); (B) pellitorine (1); (C) 8,9-Z-dehydropellitorine (2); (D) compound 3; (E) compounds 4 + 5; (F) anacycline (6); (B–E) 0.1 mg/mL; * denotes a solvent impurity also appearing in a blank chromatogram.

2.3. Antiprotozoal Activity of Isolated Alkamides

The isolated compounds were tested for their antiprotozoal activity (see Table 1). The main constituent, pellitorine (1) was found to be the most active compound against Pf, with an IC₅₀ of 3.26 µg/mL (14.6 µM). The antiplasmodial activity of 1 is thus about 2-fold higher than that of the crude extract and it also presents a higher selectivity index against this parasite than the extract. It can hence be concluded that this compound is mainly responsible for the activity of the latter against Pf. It is interesting to note that contradictory information exists in the literature with respect to the antiplasmodial activity of this compound. While pellitorine has been reported inactive up to a concentration of 20 µg/mL against the K1 strain of Pf [15], earlier authors reported an IC₅₀ of of 5.4 µg/mL for N-isobutyldeca-2,4-diene (double bond geometry not specifically mentioned) against this same strain [16]. Our results therefore confirm the previous finding.
Compound 2 (8,9-Z-dehydropellitorine) was found the most active of the isolated alkamides against *Tbr*. Its IC$_{50}$ value of 2.00 µg/mL (9 µM), however, corresponds to a 3-fold lower activity in comparison with the crude extract. Its selectivity index is about 5-fold lower than that of the total extract. Therefore, the promising activity and selectivity of the total extract cannot be attributed to any of the isolated alkamides on its own.

It is hence conceivable that either some minor constituent(s) not hitherto isolated was/were responsible for the high activity of the crude extract, or that some “synergistic” effect was at work. A few additional alkamides could be detected at low concentrations, which we are currently isolating from a larger quantity of the plant material.

2.4. Antiprotozoal Activity of Further Alkamide-Containing Plant Species

In order to assess the potential activity of other Asteraceae known to contain alkamides as major chemical constituents, we have performed preliminary tests with extracts of *Echinacea purpurea* (L.) Moench (Purple Coneflower) and of *Anacyclus pyrethrum* (L.) Lag. (Spanish Pellitory), both well known for their alkamide content [12,13,17]. Both were found to exhibit significant activity against *Pf* with IC$_{50}$s < 10 µg/mL. *E. purpurea* showed activity in the same concentration range against *Tbr* while *A. pyrethrum* was distinctly less active against the latter parasite but showed activity at a similar level against *Ldo* (see Table 1). Both species will therefore be included in further studies. It should not remain unmentioned that other authors have recently reported independently on the antiplasmodial activity of an ethyl acetate extract of *A. pyrethrum* roots, without further specification of the active constituents or an IC$_{50}$ value [18]. We report here for the first time that these roots also show activity against *L. donovani*. An extract preparation from aerial parts of *E. purpurea* has previously been described as having antityrpanosomal and antileishmanial activity. However, in this case, an aqueous extract was used and the reported inhibitory concentrations were in the mg/mL concentration range. Moreover, no indications on the chemical compounds responsible for these effects were made [19].

3. Experimental

3.1. Analytical Procedures and Instrumentation

3.1.1. Preparative High-Performance Liquid Chromatography (HPLC)

All separations were performed on a Waters preparative HPLC system (Waters 515 pumps with a Knauer single wavelength detector at 260 nm, Degasys DG 2410; Embase software) on a Chrom Hypersil ODS C-18 column (5 µm, 250 × 16 mm) column. Three different methods were established using binary gradients of water (A) and acetonitrile (B) and a flow rate of 10 mL/min:

Method 1: 0 to 25 min: linear from 40% B to 100% B; 25 to 35 min: isocratic 100% B.

Method 2: 0 to 20 min: linear from 30% to 40% B; 20 to 25 min: linear from 40% to 60% B; 25 to 30 min: linear from 60% to 100% B; 30 to 40 min: isocratic 100% B.

Method 3: 0 to 5 min: linear from 40% to 55% B; 5 to 25 min: isocratic 55% B; from 25 to 30 min: linear from 55% to 100% B; 30 to 50 min: isocratic 100% B.
3.1.2. UHPLC/+ESI-QTOF-MS/MS

High-resolution mass determinations were performed on a Dionex Ultimate 3000 RS Liquid Chromatography System on a Dionex Acclaim RS LC 120, C18 column (2.1 × 100 mm, 2.2 µm) with a binary gradient (A: water with 0.1% formic acid; B: acetonitrile with 0.1% formic acid) at 0.8 mL/min: 0 to 9.5 min: linear from 5% B to 100% B; 9.5 to 12.5 min: isocratic 100% B; 12.5 to 12.6 min: linear from 100% B to 5% B; 12.6 to 15 min: isocratic 5% B. The injection volume was 2 µL. Eluted compounds were detected using a Dionex Ultimate DAD-3000 RS over a wavelength range of 200–400 nm and a Bruker Daltonics micrOTOF-Q II time-of-flight mass spectrometer equipped with an Apollo electrospray ionization source in positive mode at 5 Hz over a mass range of \( m/z \) 50–1,000 using the following instrument settings: nebulizer gas nitrogen, 5 bar; dry gas nitrogen, 9 L/min, 220 °C; capillary voltage 4,500 V; end plate offset −500 V; transfer time 70 µs; collision gas nitrogen; collision energy and collision RF settings were combined to each single spectrum of 1,000 summations as follows: 250 summations with 20% base collision energy and 130 Vpp + 250 summations with 100% base collision energy and 500 Vpp + 250 summations with 20% base collision energy and 130 Vpp + 250 summations with 100% base collision energy and 500 Vpp. Base collision energy was 50 eV for precursor ions with a \( m/z \) less than 500 and then linearly interpolated against \( m/z \) up to a maximum of 70 eV for precursor ions with a \( m/z \) of up to 1000. Internal dataset calibration (HPC mode) was performed for each analysis using the mass spectrum of a 10 mM solution of sodium formiate in 50% isopropanol that was infused during LC re-equilibration using a divert valve equipped with a 20 µL sample loop.

Sample concentration: concentration of pure compounds: 0.1 mg/mL in methanol; concentration of crude extract: 1 mg/mL.

3.1.3. NMR Spectroscopy

NMR spectra were recorded with a Varian AS 400 Mercuryplus spectrometer at room temperature in CDCl₃ (purity 99.8%, Merck). Spectra were referenced to the CHCl₃ solvent signal at δ 7.260 ppm.

3.2. Isolation Process

3.2.1. Plant Material

Achillea ptarmica L. was cultivated at the garden of the Institute of Pharmaceutical Biology and Phytochemistry (IPBP, Münster, Germany). Aerial parts were collected at the full flowering stage in August 2011. The plant was identified by T. J. Schmidt. A voucher specimen (# TS_AchPt_01) is deposited at the IPBP herbarium. The plant material was air-dried at room temperature and powdered with an IKA MF basic mill to the riddle mesh size of 1 mm.

3.2.2. Soxhlet Extraction

The powdered plant material (200 g) was exhaustively extracted with dichloromethane (1500 mL) in a Soxhlet apparatus for 12 h. The extract was evaporated to dryness under reduced pressure, yielding 6.89 g of crude extract.
3.2.3. Gravity Flow Column Chromatography (CC)

The extract (6.88 g) was applied on 1.2 kg of silica gel (particle size 0.063 to 0.2 mm; Merck, column dimensions: 110 × 6 cm). The silica was equilibrated at 90:10 n-hexane/EtOAc (2,400 mL). The flow was adjusted to 1 mL/min and 10 mL of the eluate were collected per tube. A gradient with increasing amount of EtOAc was used: n-hexane/EtOAc 90:10 (5 L); 80:20 (7.5 L); 70:30 (6 L); 60:40 (3.5 L); 50:50 (2.5 L); 0:100 (2.5 L). Related fractions were combined after TLC control (silica gel 60 F254, Merck (10 × 20 cm); detection: anisaldehyde/sulfuric acid, UV 254 nm, 366 nm and daylight; elution: current solvent mixture of the CC column). The fractionation is summarized in Table 3.

Table 3. CC fractionation of A. ptarmica CH₂Cl₂ extract.

| Fraction I–XIV | Combined eluates (10 mL/tube) | Elution volume (mL) | Yield (g) | Isolated compound |
|----------------|-------------------------------|---------------------|-----------|-------------------|
|                | 1–1070                        | 10,700              | 2.4906    |                   |
| Fractions XV–XVIII containing chlorophylls | 1071–1359                  | 2890                | 0.3426    |                   |
| XIX            | 1390–1460                     | 1100                | 0.0889    |                   |
| XX             | 1461–1560                     | 1000                | 0.3034    |                   |
| XXI            | 1561–1600                     | 400                 | 0.2738    | 1                 |
| XXII           | 1601–1780                     | 1800                | 0.4904    | 2                 |
| XXIII          | 1781–1920                     | 2200                | 0.1344    | 6                 |
| XXIV           | 2001–2070                     | 700                 | 0.0187    |                   |
| XXV            | 2071–2120                     | 500                 | 0.0635    | 3, 4 + 5          |
| XXVI           | 2121–2160                     | 400                 | 0.0196    |                   |
| XXVII          | 2161–2310                     | 1500                | 0.1627    |                   |
| XXVIII         | 950                           | 0.1017              |           | 3, 4 + 5          |
| XXVIX          | 940                           | 0.1139              |           |                   |
| XXX            | 4920                          | empty               |           |                   |
| total          | 30,000                        | 4.6042              |           |                   |

3.2.4. Purification of the Alkaloids by Preparative High Performance Liquid Chromatography (prep. HPLC)

Pellitorine (1) was isolated in a yield of 3.2 mg from 64.9 mg of fraction XXI using HPLC method 1. A portion of fraction XXII (34.3 mg), after purification with HPLC method I, yielded 1.7 mg of 8,9-Z-dehydropellitorine (2). Compound 3 (1.7 mg) and the mixture of compounds 4 and 5 (3.0 mg) were obtained from 30.8 mg of fraction XXVI and 89.2 mg of fraction XXVIII after HPLC separation using method 2. Anacycline (6) was purified from 86 mg of fraction XXIII using HPLC method 3 which yielded 1.3 mg of 6. All compounds were obtained as slightly yellowish oils.

3.2.5. Analytical Data

(E,E)-2,4-decadienoic acid isobutylamide (pellitorine, 1) UHPLC/+ESI-QTOF MS: Rt 7.67 min, MS (m/z): 224.2020 [M+H]+; calcd. for C۱۴H۲۶NO+: 224.2020; 1H-NMR (400 MHz, CDCl₃; δ (ppm), mult., J (Hz)): 7.18 (dd, 10, 15; H-3); 6.13 (dd, 10, 15; H-4); 6.06 (dt, 15, 6; H-5); 5.75 (d, 15, H-2);
5.48 (br t, ≈5, NH); 3.16 (dd (2H), 6, 7; H-2'); 2.14 (dt [q] (2H), ≈6, 7; H-6); 1.80 (sept, 7, H-3'); 1.41 (quint (2H), 7, 15; H-7); 1.28 (m (4H); H-8, H-9); 0.92 (d (6H), 7, H-4', 5'); 0.88 (t (3H), 7, H-10).

(E,E,Z)-2,4,8-decatrienoic acid isobutylamide (8,9-dehydropellitorine 2) UHPLC/+ESI-QTOF MS: Rt 7.05 min, MS (m/z): 222.1855 [M+H]+; calcd. for C24H24NO+: 222.1855); 1H-NMR (400 MHz, CDCl3; δ (ppm), mult., J (Hz)): 7.19 (dd, 10, 15; H-3); 6.15 (dd, 10, 15; H-4); 6.07 (dt, 15, 6; H-5); 5.75 (d, 15, H-2); 5.47 (dqt, 11, 7, 1; H-9); 5.38 (dtq, 11, 7, 1; H-8); 3.16 (dd (2H), 6, 7; H-2'); 2.20 (m (4H), H-6, 7); 1.81 (sept., 7, H-3'); 1.60 (br d (3H), ≈7; H-10); 0.92 (d (6H), 7, H-4', 5').

(E,E)-2,4,undecadien-8,10-diynoic acid isobutylamide (3) UHPLC/+ESI-QTOF MS: RT 6.44 min, MS (m/z): 230.1541 [M+H] + (calcd. for C 15H20NO+: 230.1539); 1H-NMR (400 MHz, CDCl3; δ (ppm), mult., J (Hz)): 7.19 (dd, 11, 15; H-3); 6.20 (dd, 11, 15; H-4); 6.05 (dt, 15, 7; H-5); 5.80 (d, 15, H-2); 5.48 (br t, ≈5, NH); 3.16 (dd (2H), 6, 7; H-2'); 2.39 (m (4H), H-6, 7); 1.98 (s, H-11); 1.80 (sept., 7, H-3'); 0.93 (d (6H), 7, H-4', 5').

(E,E)-2,4-undecadien-8,10-diynoic acid piperidide (4) UHPLC/+ESI-QTOF MS: Rt 6.73 min, MS (m/z): 242.1546 (calcd. for C 16H20NO+: 242.1539); 1H-NMR (400 MHz, CDCl3; δ (ppm), mult., J (Hz)): 7.18 (dd, 10, 15; H-3); 6.31 (d, 15, H-2); 6.25 (dd, 11, 15; H-4); 6.02 (dt, 15, 7; H-5); 3.61 (m (2H); H-2',6'); 3.49 (m (2H); H-2',6'); 2.39 (m (4H), H-6, 7); 1.98 (s, H-11); 1.5-1.75 (m; H-3', 4', 5').

(E,E)-2,4-tetradecadien-8,10-diynoic acid phenethylamide (5) UHPLC/+ESI-QTOF MS: Rt 6.91 min, MS (m/z): 278.1542 (calcd. for C 19H20NO+: 278.1539); 1H-NMR (400 MHz, CDCl3; δ (ppm), mult., J (Hz)): 7.25-7.35 (m; aro H); 7.20 (dd, 10, 15; H-3); 6.18 (dd, 10, 15; H-4); 6.02 (dt, 15, 7; H-5); 5.73 (d, 15, H-2); 5.45 (br t, ≈5, NH); 3.61 (br dt [q] (2H), ≈7; H-2'); 2.85 (t (2H), 7; H-3'); 2.39 (m (4H), H-6, 7); 1.98 (s, H-11).

All analytical data were in full agreement with literature data [11,14].

3.3. In Vitro Assays and IC50 Determination

Tests for antiprotozoal activities were carried out using established standard protocols at the Swiss Tropical and Public Health Institute (Swiss TPH, Basel, Switzerland). The assays and the IC50 determinations were performed essentially as described previously [4].

The compounds used as positive controls in the various bioassays (see Table 1) were of commercial origin, with the exception of melarsoprol, which was a gift from the WHO. Their purity (generally > 95%) was specified by the manufacturers.

The purity of test compounds was assessed by UHPLC/MS and 1H-NMR analyses and found to be >95% in case of compounds 1 and 6, >80% in case of compound 2. Compounds 4 + 5 represented a mixture in a ratio of approximately 73%:27%. Compound 3 was isolated together with about 18% 4 + 5 (compare Figure 2).
4. Conclusions

While antiprotozoal activity has been reported for various polyacetylenes obtained from the Asteraceae and other families [2,3], such activity could be shown for the first time in this study for several alkamides with a 2E,4E-diene moiety.

Pellitorine was found the most active compound against Pf whose activity is sufficiently high to explain the effect of the crude extract. Since a single alkamide matching the antitrypanosomal activity and selectivity of the crude dichloromethane extract of A. ptarmica could not yet be isolated (8,9-Z-dehydropellitorine as the most active isolated compound is about three times less active than the extract), we are currently continuing these efforts in order to isolate further compounds present in the extract at lower concentrations, which might be more active. Furthermore, combinations of alkamides will be tested in order to investigate the possibility of synergistic effects.

It is also interesting to note that extracts of E. purpurea and A. pyrethrum, both known to contain a rich variety of alkamides [12,13,15], were found active against Tbr and Pf. Even though neither of them matches the activity of A. ptarmica against Tbr, we are currently in the course of isolating and testing their alkamides which will also be of value for structure-activity studies within this new class of antiprotozoal natural products.

Acknowledgments

Thanks are due to C. Thier and J. Sendker for measuring NMR and mass spectra, respectively. This study is an activity within the ResearchNetwork Natural Products against Neglected Diseases (ResNetNPND): http://www.uni-muenster.de/ResNetNPND/.

Author Contributions

J.B.A. performed all phytochemical parts of the work and prepared a draft manuscript. M.K. and R.B. performed the biological assays. T.J.S. initiated the study, supervised the phytochemical work, coordinated the project and prepared the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Althaus, J.B.; Kaiser, M.; Brun, R.; Schmidt, T.J. Bioassay-guided isolation of alkamides from an extract of Achillea ptarmica L. with antiprotozoal activity. Planta Med. 2013, 79, 1129. doi:10.1055/s-0033-1351907.
2. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.A.; Biavatti, M.W.; Brun, R.; Da Costa, F.B.; de Castro, S.L.; Ferreira, V.F.; de Lacerda, M.V.G.; et al. The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases—Part I. Curr. Med. Chem. 2012, 19, 2128–2175.
3. Schmidt, T.J.; Khalid, S.A.; Romanha, A.J.; Alves, T.M.A.; Biavatti, M.W.; Brun, R.; Da Costa, F.B.; de Castro, S.L.; Ferreira, V.F.; de Lacerda, M.V.G.; et al. The potential of secondary
metabolites from plants as drugs or leads against protozoan neglected diseases—Part II. *Curr. Med. Chem.* 2012, 19, 2176–2228.
4. Schmidt, T.J.; Nour, A.M.M.; Khalid, S.A.; Kaiser, M.; Brun, R. Quantitative Structure-Antiprotozoal Activity Relationships of Sesquiterpene Lactones. *Molecules* 2009, 14, 2062–2076.
5. Schmidt, T.J.; Da Costa, F.B.; Lopes, N.P.; Kaiser, M.; Brun, R. *In silico* prediction and experimental evaluation of furanoheliangolide sesquiterpene lactones as potent agents against *Trypanosoma brucei rhodesiense*. *Antimicrob. Agents Chemother.* 2014, 58, 325–332.
6. Nour, A.M.M.; Khalid, S.A.; Brun, R.; Kaiser, M.; Schmidt, T.J. The antiprotozoal activity of methylated flavonoids from *Ageratum conyzoides* L. *J. Ethnopharmacol.* 2010, 129, 127–130.
7. Harel, D.; Khalid, S.A.; Kaiser, M.; Brun, R.; Wünsch, B.; Schmidt, T.J. Encecalol angelate, an unstable chromene from *Ageratum conyzoides* L.: Total Synthesis and Investigation of its Antiprotozoal Activity. *J. Ethnopharmacol.* 2011, 137, 620–625.
8. Kuropka G.; Neugebauer, M.; Glombitza, K.W. Essential Oils of *Achillea ptarmica*. *Planta Med.* 1991, 57, 492–494.
9. Valant-Vetschera, K. Flavonoid diversification in *Achillea ptarmica* and allied taxa. *Biochem. Syst. Ecol.* 1985, 13, 15–21.
10. Kuropka, G.; Koch, M.; Glombitza, K.-W. Säureamide aus *Achillea ptarmica* (Acid amides from *Achillea ptarmica*). *Planta Med.* 1986, 244–245.
11. Kuropka, G.; Glombitza, K.W. Further Polyenic and Polyynic Carboxamides and Sesamin from *Achillea ptarmica*. *Planta Med.* 1987, 53, 440–442.
12. Greger, H. Alkamides: Structural Relationships, Distribution and Biological Activity. *Planta Med.* 1984, 50, 366–375.
13. Woelkart, K.; Bauer, R. The role of alkamides as an active principle of *Echinacea*. *Planta Med.* 2007, 73, 615–623.
14. Hofer, O.; Greger, H.; Robien, W.; Werner, A. $^{13}$C-NMR and $^1$H lanthanide induced shifts of naturally occurring alkamides with cyclic amide moieties—Amides from *Achillea falcata*. *Tetrahedron* 1986, 42, 2707–2716.
15. Rukachaisirikul, T.; Siriwattanakit, P.; Sukcharoenphol, K.; Wongvein, C.; Ruttanaweang, P.; Wongwattanavuch, P.; Suksamrarn, A. Chemical constituents and bioactivity of *Piper sarmentosum*. *J. Ethnopharmacol.* 2004, 93, 173–176.
16. Weenen, H.; Nkunya, M.H.H.; Bray, D.H.; Mwasumbi, L.B.; Kinabo, L.S.; Kilimali, V.A.E.B.; Wijnberg, J.B.P.A. Antimalarial Compounds Containing an α,β-Unsaturated Carbonyl Moiety from Tanzanian Medicinal Plants. *Planta Med.* 1990, 56, 371–373.
17. Christensen, L.P. Acetylenes and related compounds in Anthemideae. *Phytochemistry* 1992, 31, 7–49.
18. Zimmermann, S.; Thomi, S.; Kaiser, M.; Hamburger, M.; Adams, M. Screening and HPLC-Based Activity Profiling for New Antiprotozoal Leads from European Plants. *Sci. Pharm.* 2012, 80, 205–213.
19. Canlas, J.; Hudson, J.B.; Sharma, M.; Nandan, D. *Echinacea* and trypanosomatid parasite interactions: Growth-inhibitory and anti-inflammatory effects of *Echinacea*. *Pharm. Biol.* 2010, 48, 1047–1052.

**Sample Availability:** Samples of the compounds 1–6 are available from the authors.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).